Financial StabilityKOD ended with $168M in cash, which is projected to support them through the upcoming years, indicating a stable financial position.
New OpportunitiesReformulated tarcocimab and ABC pipeline are seen as new opportunities for the company.
Strategic PositioningThe company has taken appropriate strategic steps to position the ABCD platform for its best shots on goal, focusing on enhanced formulation tarcocimab and other trials.